<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Kidney Med</journal-id><journal-id journal-id-type="iso-abbrev">Kidney Med</journal-id><journal-title-group><journal-title>Kidney Medicine</journal-title></journal-title-group><issn pub-type="epub">2590-0595</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35765466</article-id><article-id pub-id-type="pmc">PMC9222405</article-id><article-id pub-id-type="pii">S2590-0595(22)00123-6</article-id><article-id pub-id-type="doi">10.1016/j.xkme.2022.100502</article-id><article-id pub-id-type="publisher-id">100502</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject><subj-group><subject>Letter to the Editor</subject></subj-group></subj-group></article-categories><title-group><article-title>Kidney Transplant Recipients With COVID-19 and Monoclonal Antibody Therapy: Additional Considerations</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Mungmunpuntipantip</surname><given-names>Rujittika</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Wiwanitkit</surname><given-names>Viroj</given-names></name><degrees>MD</degrees><xref rid="aff2" ref-type="aff">2</xref></contrib><aff id="aff1"><label>1</label>Private Academic Consultant, Bangkok Thailand</aff><aff id="aff2"><label>2</label>Dr DY Patil University, Pune, India</aff></contrib-group><pub-date pub-type="pmc-release"><day>23</day><month>6</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>8</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2022</year></pub-date><volume>4</volume><issue>8</issue><elocation-id>100502</elocation-id><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d35e14" ext-link-type="doi" xlink:href="10.1016/j.xkme.2022.100470"/></article-meta></front><body><p content-type="salutation">To the Editor:</p><p id="p0010">We read with interest the recent article in which Fernandes et&#x000a0;al<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> found that neutralizing monoclonal antibody therapy was associated with favorable outcomes among kidney transplant recipients presenting with mild COVID-19. We agree that neutralizing monoclonal antibody treatment may be beneficial. However, we highlight that additional information on patients&#x02019; immunologic state would be useful, including recent receipt of other transplant immunosuppression and underlying health conditions that may impact the susceptibility to developing severe COVID-19. Additionally, we wondered if any of these individuals had experienced past SARS-CoV-2 infection. In combination with vaccination, prior infection may reduce the risk of severe COVID-19.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref></p></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>G.</given-names></name><name><surname>Devresse</surname><given-names>A.</given-names></name><name><surname>Scohy</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Monoclonal antibody therapy in kidney transplant recipients with delta and omicron variants of SARS-CoV-2: a single-center case series</article-title><source>Kidney Med</source><volume>4</volume><issue>6</issue><year>2022</year><object-id pub-id-type="publisher-id">100470</object-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Joob</surname><given-names>B.</given-names></name><name><surname>Wiwanitkit</surname><given-names>V.</given-names></name></person-group><article-title>Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period</article-title><source>J&#x000a0;Prev Med Public Health</source><volume>53</volume><issue>2</issue><year>2020</year><fpage>70</fpage><pub-id pub-id-type="pmid">32268458</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Article Information</title><sec id="sec1"><title>Financial Disclosure</title><p id="p0015">The authors declare that they have no relevant financial interests.</p></sec><sec id="sec2"><title>Peer Review</title><p id="p0020">Received May 2, 2022. Direct editorial input from the Editor-in-Chief. Accepted in revised form May 11,&#x000a0;2022.</p></sec></ack></back></article>
